Vopimetostat not checked

Tango Therapeutics, Inc. · TNG462

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
4 active
4 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“TNG462, a selective PRMT5 inhibitor, will be administered orally”In the company’s words, NCT05732831 on ClinicalTrials.gov
Tested for
PDAC (2 trials), PDAC - Pancreatic Ductal Adenocarcinoma (2 trials), NSCLC (2 trials), RAS Mutation (2 trials), MTAP Deletion (2 trials), Lung Cancer (2 trials), Pancreatic Cancer Metastatic (2 trials), Thoracic Cancer (2 trials) and 2 more
Main trialPhase 1/2
“This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.”In the company’s words, NCT06188702 on ClinicalTrials.gov
Other names
TNG462

Other drugs for PDAC

All 203 drugs for PDAC

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 1 May 2027 S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2Recruiting Jun 2027 Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/2Recruiting Jun 2027 Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Phase 1/2Not yet recruiting Nov 2031 TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Vopimetostat

Following is part of Solo: you see every change to Vopimetostat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in